Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2006 | Original article

Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease

Authors: Takashi Kawachi, Kazunari Ishii, Setsu Sakamoto, Masahiro Sasaki, Tetsuya Mori, Fumio Yamashita, Hiroshi Matsuda, Etsuro Mori

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2006

Abstract.

Purpose

The aim of this study was to compare the diagnostic performance of¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and voxel-based morphometry (VBM) on magnetic resonance imaging (MRI) in the same group of patients with very mild Alzheimer’s disease (AD).

Methods

Thirty patients with very mild AD (age 67.0±5.8 years; MMSE score 25.5±1.2, range 24–28), 32 patients with mild AD (age 67.0±4.5 years, MMSE score 22.1±0.8, range 21–23) and 60 age- and sex-matched normal volunteers underwent both FDG-PET and three-dimensional spoiled gradient echo MRI. Statistical parametric mapping was used to conduct voxel by voxel analysis and Z score mapping. First, the region of interest (ROI) maps of significant reductions in glucose metabolism and grey matter density in the mild AD patients were defined. Secondly, analysis of receiver operating characteristic (ROC) curves for Z scores in the ROI maps discriminating very mild AD patients and normal controls was performed.

Results

In mild AD patients, FDG-PET indicated significant reductions in glucose metabolism in the bilateral posterior cingulate gyri and the right parietotemporal area, while VBM analysis showed a significant decrease in grey matter volume density in the bilateral amygdala/hippocampus complex, compared with the normal control group. ROC analysis showed that in very mild AD patients the accuracy of FDG-PET diagnosis was 89% and that of VBM-MRI diagnosis was 83%. The accuracy of the combination of FDG-PET and VBM-MRI diagnosis was 94%.

Conclusion

In very mild AD, both FDG-PET and VBM-MRI had high accuracy for diagnosis, but FDG-PET showed slightly higher accuracy than VBM-MRI. Combination of the two techniques will yield a higher diagnostic accuracy in very mild AD by making full use of functional and morphological images.

Grundman M, Sencakova D, Jack CR Jr, Petersen RC, Kim HT, Schultz A, et al. Alzheimer’s Disease Cooperative Study. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002;19:23–27PubMedCrossRef

Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, et al. Global and local gray matter loss in mild cognitive impairment and Alzheimer’s disease. Neuroimage 2004;23:708–716PubMedCrossRef

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. MRI and CSF studies in the early diagnosis of Alzheimer’s disease. J Intern Med 2004;256:205–223PubMedCrossRef

de Toledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004;25:1197–1203CrossRef

Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94PubMedCrossRef

Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32:486–510PubMedCrossRef

Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332–2340PubMed

Herholz K. PET studies in dementia.Ann Nucl Med 2003;17:79–89PubMed

Ashburner J, Friston KJ. Voxel-based morphometry—the methods. Neuroimage 2000;11:805–821PubMedCrossRef

10.

Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer’s disease. Neuroimage 2001;14:298–309PubMedCrossRef

11.

Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618–630PubMedCrossRef

12.

Ishii K, Kawachi T, Sasaki H, Kono AK, Fukuda T, Kojima Y, et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer’s disease and assessment of diagnostic performance of Z score images. AJNR Am J Neuroradiol 2005;25:333–340

13.

Ishii K, Sasaki H, Kono AK, Miyamoto N, Fukuda T, Mori E. Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2005;32:959–963PubMedCrossRef

14.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939–944PubMed

15.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12:189–198PubMedCrossRef

16.

Honma A, Fukuzawa K, Tsukada Y, Ishii T, Hasegawa K, Mohs RC. Development of a Japanese version of Alzheimer’s Disease Assessment Scale (ADAS). Jpn J Geriatr Psychiatry 1992;647–655

17.

Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer’s disease. J Nucl Med 1997;38:925–928PubMed

18.

Friston KJ, Ashburner J, Frith CD, Poline J-B, Heather JD, Frackowiak RSJ. Spatial registration and normalization of images. Human Brain Mapping 1995;3:165–189CrossRef

19.

Ashburner J, Neelin P, Collins DL, Evans AC, Friston KJ. Incorporating prior knowledge into image registration. Neuroimage 1997;6:344–352PubMedCrossRef

20.

Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Human Brain Mapping 1999;7:254–266PubMedCrossRef

21.

Ishii K, Sasaki M, Matsui M, Sakamoto S, Yamaji S, Hayashi N, et al. A diagnostic method for suspected Alzheimer’s disease using H₂ ¹⁵O positron emission tomography perfusion Z score. Neuroradiology 2000;42:787–794PubMedCrossRef

22.

Bookstein FL. “Voxel-based morphometry” should not be used with imperfectly registered images. Neuroimage 2001;14:1454–1462PubMedCrossRef

23.

Ashburner J, Friston KJ. Why voxel-based morphometry should be used. Neuroimage 2001;14:1238–1243PubMedCrossRef

24.

Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal atrophy in Alzheimer’s disease. Neurology 1991;41:51–54PubMed

25.

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–972PubMedCrossRef

26.

Jack CR, Petersen RC, O’Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 1992;42:183–188PubMed

27.

Watson C, Andermann F, Gloor P, Jones-Gotman M, Peters T, Evans A, et al. Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology 1992;42:1743–1750PubMed

28.

de Leon MJ, Golomb J, George AE, Convit A, Tarshish CY, McRae T, et al. The radiologic prediction of Alzheimer’s disease: the atrophic hippocampal formation. AJNR 1993;14:897–906PubMed

29.

Kiliany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer’s disease. Arch Neurol 1993;50:949–954

30.

Lehéricy S, Baulac M, Chiras J, Pierot L, Martin N, Pillon B, et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer’s disease. AJNR 1994;15:927–937

31.

Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 2002;13:1939–19343PubMedCrossRef

32.

Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005;64:1860–1867PubMedCrossRef

33.

Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 1996;198:837–843PubMed

34.

Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Demonstration of decreased posterior cingulate perfusion in mild Alzheimer’s disease by means of H₂ ¹⁵O positron emission tomography. Eur J Nucl Med 1997;24:670–673PubMed

35.

Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 2002;16:515–525PubMedCrossRef

36.

Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mosch D, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer’s disease by SPECT. J Nucl Med 1997;38:1095–1101PubMed

37.

Kanetaka H, Matsuda H, Asada T, Ohnishi T, Yamashita F, Imabayashi E, et al. Effects of partial volume correction on discrimination between very early Alzheimer’s dementia and controls using brain perfusion SPECT. Eur J Nucl Med Mol Imaging 2004;31:975–980PubMedCrossRef

38.

Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998;39:1875–1878PubMed

39.

Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology 1998;51:125–130PubMed

40.

Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, et al. Frontal lobe hypometabolism and depression in Alzheimer’s disease. Neurology 1998;50:380–383PubMed

41.

Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, et al. Regional hypometabolism related to language disturbance in Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:68–73PubMedCrossRef

42.

Hirono N, Mori E, Ishii K, Kitagaki H, Sasaki M, Ikejiri Y, et al. Alteration of regional cerebral glucose utilization with delusions in Alzheimer’s disease. J Neuropsychiat Clin Neurosci 1998;10:433–439

Title: Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease
Authors: Takashi Kawachi
Kazunari Ishii
Setsu Sakamoto
Masahiro Sasaki
Tetsuya Mori
Fumio Yamashita
Hiroshi Matsuda
Etsuro Mori
Publication date: 01-07-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0050-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease

Abstract.

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract.

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2006

The role of FDG-PET/CT in the detection of recurrent colorectal cancer

Submillimetre spatial resolution is feasible in positron emission tomography

Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer

In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF

The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment

Persistent aseptic meningitis due to post-surgical spinal CSF leakage: value of fused 111mIn-DTPA SPECT-CT cisternography